{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:25:33Z","timestamp":1762899933108},"reference-count":10,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cell Commun. Signal."],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>One of the first targets proposed as an anti-fibrotic therapy was CCN2. Proof of its involvement in fibrosis was initially difficult, due to the lack of appropriate reagents and general understanding of the molecular mechanisms responsible for persistent fibrosis. As these issues have been progressively resolved over the last twenty-five years, it has become clear that CCN2 is a bone fide target for anti-fibrotic intervention. An anti-CCN2 antibody (FG-3019) is in Phase III clinical trials for idiopathic pulmonary fibrosis and pancreatic cancer, and in Phase II for Duschenne\u2019s muscular dystrophy. An exciting paper recently published by Mary Barbe and the Popoff group has shown that FG-3019 reduces established muscle fibrosis (Barbe et al., FASEB J 34:6554\u20136569, 2020). Intriguingly, FG-3019 blocked the decreased expression of the anti-fibrotic protein CCN3, caused by the injury model. These important data support the notion that targeting CCN2 in the fibrotic microenvironment may reverse established fibrosis, making it the first agent currently in development to do so.<\/jats:p>","DOI":"10.1007\/s12079-020-00568-1","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T06:02:37Z","timestamp":1589436157000},"page":"349-350","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Slow train coming: an anti-CCN2 strategy reverses a model of chronic overuse muscle fibrosis"],"prefix":"10.1002","volume":"14","author":[{"given":"Andrew","family":"Leask","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,5,14]]},"reference":[{"key":"568_CR1","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/jor.24337","volume":"37","author":"MF Barbe","year":"2019","unstructured":"Barbe MF, Hilliard BA, Delany SP, Iannarone VJ, Harris MY, Amin M, Cruz GE, Barreto-Cruz Y, Tran N, Day EP, Hobson LJ, Assari S, Popoff SN (2019) Blocking CCN2 reduces progression of sensorimotor declines and fibrosis in a rat model of chronic repetitive overuse. J Orthop Res 37:2004\u20132018","journal-title":"J Orthop Res"},{"key":"568_CR2","doi-asserted-by":"publisher","unstructured":"Barbe MF, Hilliard BA, Amin M, Harris MY, Hobson LJ, Cruz GE, Popoff SN (2020 Mar 29) Blocking CTGF\/CCN2 reduces established skeletal muscle fibrosis in a rat model of overuse injury. FASEB J 34:6554\u20136569. https:\/\/doi.org\/10.1096\/fj.202000240RR. [Epub ahead of print]","DOI":"10.1096\/fj.202000240RR"},{"key":"568_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S1359-6101(97)00010-5","volume":"8","author":"GR Grotendorst","year":"1997","unstructured":"Grotendorst GR (1997) Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev 8:171\u2013179","journal-title":"Cytokine Growth Factor Rev"},{"key":"568_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s12079-019-00520-y","volume":"13","author":"A Leask","year":"2019","unstructured":"Leask A (2019) Breathe, breathe in the air: the anti-CCN2 antibody pamrevlumab (FG-3019) completes a successful phase II clinical trial for idiopathic pulmonary fibrosis. J Cell Commun Signal 13:441\u2013442","journal-title":"J Cell Commun Signal"},{"key":"568_CR5","doi-asserted-by":"publisher","unstructured":"Leask A (2020, 2020 Mar 4) Conjunction junction, what\u2019s the function? CCN proteins as targets in fibrosis and cancers. Am J Physiol Cell Physiol. https:\/\/doi.org\/10.1152\/ajpcell.00028.2020 [Epub ahead of print]","DOI":"10.1152\/ajpcell.00028.2020"},{"key":"568_CR6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00441-018-2955-2","volume":"375","author":"MAA Mahdy","year":"2019","unstructured":"Mahdy MAA (2019) Skeletal muscle fibrosis: an overview. Cell Tissue Res 375:575\u2013588","journal-title":"Cell Tissue Res"},{"key":"568_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s12079-018-0491-1","volume":"12","author":"B Perbal","year":"2018","unstructured":"Perbal B, Tweedie S, Bruford E (2018) The official unified nomenclature adopted by the HGNC calls for the use of the acronyms, CCN1-6, and discontinuation in the use of CYR61, CTGF, NOV and WISP 1\u20133 respectively. J Cell Commun Signal 12:625\u2013629","journal-title":"J Cell Commun Signal"},{"key":"568_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S2213-2600(19)30262-0","volume":"8","author":"L Richeldi","year":"2020","unstructured":"Richeldi L, Fern\u00e1ndez P\u00e9rez ER, Costabel U, Albera C, Lederer DJ, Flaherty KR, Ettinger N, Perez R, Scholand MB, Goldin J, Peony Yu KH, Neff T, Porter S, Zhong M, Gorina E, Kouchakji E, Raghu G (2020) Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, doubleblind, placebo-controlled trial. Lancet Respir Med 8:25\u201333","journal-title":"Lancet Respir Med"},{"key":"568_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12079-015-0309-3","volume":"9","author":"BL Riser","year":"2015","unstructured":"Riser BL, Barnes JL, Varani J (2015) Balanced regulation of the CCN family of matricellular proteins: a novel approach to the prevention and treatment of fibrosis and cancer. J Cell Commun Signal 9:327\u2013339","journal-title":"J Cell Commun Signal"},{"key":"568_CR10","doi-asserted-by":"crossref","unstructured":"Tsang M, Quesnel K, Vincent K, Hutchenreuther J, Postovit LM, Leask A. 2020 Insights into fibroblast plasticity: cellular communication network 2 is required for activation of cancer-associated fibroblasts in a murine model of melanoma. Am J Pathol 1=90: 206\u2013221","DOI":"10.1016\/j.ajpath.2019.09.006"}],"container-title":["Journal of Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12079-020-00568-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12079-020-00568-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12079-020-00568-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T19:07:57Z","timestamp":1702667277000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12079-020-00568-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,14]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["568"],"URL":"https:\/\/doi.org\/10.1007\/s12079-020-00568-1","relation":{},"ISSN":["1873-9601","1873-961X"],"issn-type":[{"value":"1873-9601","type":"print"},{"value":"1873-961X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,14]]},"assertion":[{"value":"14 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}